Reproducible Clinical Response and Serial Electrophysiological Improvement With Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy
Open Access
- 9 November 2026
- journal article
- Published by Wiley in Clinical and Experimental Neuroimmunology
- Vol. 17 (4)
Abstract
Background: Efgartigimod has emerged as a treatment option for chronic inflammatory demyelinating polyneuropathy (CIDP); however, longitudinal electrophysiological changes during treatment and the clinical course after treatment withdrawal remain incompletely characterized. Case Presentation: A woman in her 40s with CIDP showed a favorable but transient response to intravenous immunoglobulin and subsequently received subcutaneous efgartigimod as maintenance therapy. Clinical improvement was accompanied by marked electrophysiological recovery, including restoration of median sensory nerve action potentials and improvement in motor conduction parameters. After approximately 1 year of clinical stability, treatment was temporarily withdrawn, followed by clinical relapse approximately 3 weeks later. After efgartigimod reintroduction, improvement again became apparent after approximately the third administration, closely reproducing the initial treatment course. Conclusions: The relapse after efgartigimod withdrawal and reproducible improvement after reintroduction support the potential role of efgartigimod as maintenance therapy in this patient. Serial nerve conduction studies may provide an objective adjunct for assessing electrophysiological response during treatment.Keywords
This publication has 4 references indexed in Scilit:
- Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort studyFrontiers in Immunology, 2026
- CIDP Treatment Outcomes Correlation With First Nerve Conduction Changes: Ascertainment of Initial and Long‐Term RespondersJournal of the Peripheral Nervous System, 2025
- Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathyBrain, 2022
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansJournal of Clinical Investigation, 2018